Effects of Liujunzi Decoction on the Quality of Life of Patients with Advanced Primary Liver Cancer: A Meta-analysis_Chinese Journal of Evidence-Based Medicine

Authors：

 ZHAOXiu-xiu ^# ,  LIBo ^# ,  WUYu

Department of Oncology, Xiyuan Hospital, China Academy of Medical Science, Beijing 100091, China;

Corresponding author：

WUYu, Email: wuyu713@vip.sina.com

Keywords：

Liujunzi decoction; Advanced primary liver cancer; Quality of life; Systematic review; Meta-analysis; Randomized controlled trial

DOI：

10.7507/1672-2531.20160018

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the effects of Liujunzi decoction on improving the quality of life (QOL) of patients with advanced primary liver cancer. Methods Databases including MEDLINE, EMbase, SCI, The Cochrane Library (Issue 2, 2014), CBM, CNKI, VIP and WanFang Data were searched electronically from inception to July 2014 to collect randomized controlled trials (RCTs) about Liujunzi Decoction for advanced primary liver cancer. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then, meta-analysis was performed by using RevMan 5.3 software. Results A total of 7 RCTs involving 458 patients were included. The results of meta-analysis showed that the Liujunzi decoction group had significantly higher stability of QOL (RR=0.76, 95%CI 0.64 to 0.91, P=0.002), Karnofsky Performance Score (KPS) (MD=4.47, 95%CI 2.74 to 6.21, P<0.00001) and effective rate of TCM syndrome (RR=0.73, 95%CI 0.62 to 0.86, P=0.0001) than those of the control group. Conclusion Current evidence shows that Liujunzi decoction could improve the QOL and KPS, and relieve TCM syndromes of patients with advanced primary liver cancer, especially for those with spleen deficiency-syndrome. Due to the limited quantity and quality of the included studies, the above conclusion still needs to be verified by carrying out more high-quality RCTs.

Citation： ZHAOXiu-xiu, LIBo, WUYu. Effects of Liujunzi Decoction on the Quality of Life of Patients with Advanced Primary Liver Cancer: A Meta-analysis. Chinese Journal of Evidence-Based Medicine, 2016, 16(1): 96-101. doi: 10.7507/1672-2531.20160018 Copy

1.	潘敏求, 潘博. 原发性肝癌中医临床和实验研究的回顾与展望. 湖南中医杂志, 2002, 18(4): 1-3.
2.	中华人民共和国卫生部医政司, 主编. 中国常见恶性肿瘤诊治规范. 第29分册. 原发性肝癌. 第2版. 北京: 北京医科大学中国协和医科大学联合出版社, 1991: 10-11, 54-55.
3.	杨秉辉, 任正刚, 汤钊酞. 原发性肝癌临床分期之推荐意见. 世界华人消化杂志, 2000, 8(4):441.
4.	覃清清, 韦劲松, 许瑞琪, 等. 健脾扶正汤对晚期原发性肝癌患者生活质量的影响. 中医学报, 2013, 28(5): 632-634.
5.	Gehan EA, Tefftr MC. Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)?. J Natl Cancer Inst, 2000, 92(3): 179-181.
6.	中华人民共和国卫生部. 中药新药临床研究指导原则. 1997-06-36.
7.	李博, 李峰, 吴泰相. 参附脱毒胶囊治疗阿片类急性戒断综合征的系统评价. 中国循证医学杂志, 2005, 10(9): 684-691.
8.	钟文昭, 吴一龙, 谷力加. Review Manager (RevMan)----临床医师通向Meta 分析的桥梁. 循证医学, 2013, 3(4): 234-246.
9.	秦献魁, 李萍, 刘建平. 小柴胡汤治疗慢性乙型肝炎随机对照试验的系统评价. 中西医结合学报, 2010, 8(4): 312-320.
10.	黄智芬, 黎汉中, 陈蔚, 等. 健脾消积口服液改善晚期肝癌患者生存质量32例临床观察. 中医杂志, 2004, 45(10): 751-756.
11.	黄智芬, 黎汉忠, 陆永奎, 等. 健脾消积口服液结合西药治疗II、III期肝癌40例的临床观察. 中国中西医结合杂志, 2003, 10(3): 192-194.
12.	黄能, 刘俊波, 黄常江. 健脾消痞汤治疗中晚期原发性肝癌32例. 中华实用中西医杂志, 2006, 8(9): 1161-1162.
13.	陈强松, 裴润琼, 欧武, 等. 健脾养肝汤治疗中晚期肝癌临床研究.中医学报, 2010, 9(5): 830-831.
14.	陆群英, 李坚, 彭海燕. 柴芍六君子汤对晚期原发性肝癌患者生活质量的影响.中医学报, 2014, 8(5): 637-638.
15.	覃清清, 韦劲松, 许瑞琪. 健脾扶正汤对晚期原发性肝癌患者生活质量的影响.中医学报, 2013, 9(5): 632-634.
16.	陈敏, 沈健, 周徐涛. 中西医结合治疗中晚期乙肝病毒性肝癌疗效观察. 实用中医药杂志, 2014, 7(1): 29-30.
17.	黄智芬, 韦劲松, 黎汉忠, 等. 中医时间疗法与中西药联合治疗对晚期胃癌生存质量的影响. 中医学报, 2011, 26(8): 901-903.
18.	唐健元, 马莉, 张磊. 欧美肿瘤药物评价策略简介及思考. 中华肿瘤杂志, 2008, 30(10): 798-800.
19.	王科, 张颖. 肝癌疼痛的中医外治概况及思考. 中国医药导报, 2013, 10(15): 138-140.
20.	秦献魁, 李萍, 刘建平, 等. 小柴胡汤治疗慢性乙型肝炎随机对照试验的系统评价. 中西医结合学报, 2010, 8(4): 312-320.
21.	刘建平. 随机对照试验的报告. 中国中西医结合杂志, 2005, 25(4): 297-298.

1. 潘敏求, 潘博. 原发性肝癌中医临床和实验研究的回顾与展望. 湖南中医杂志, 2002, 18(4): 1-3.
2. 中华人民共和国卫生部医政司, 主编. 中国常见恶性肿瘤诊治规范. 第29分册. 原发性肝癌. 第2版. 北京: 北京医科大学中国协和医科大学联合出版社, 1991: 10-11, 54-55.
3. 杨秉辉, 任正刚, 汤钊酞. 原发性肝癌临床分期之推荐意见. 世界华人消化杂志, 2000, 8(4):441.
4. 覃清清, 韦劲松, 许瑞琪, 等. 健脾扶正汤对晚期原发性肝癌患者生活质量的影响. 中医学报, 2013, 28(5): 632-634.
5. Gehan EA, Tefftr MC. Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)?. J Natl Cancer Inst, 2000, 92(3): 179-181.
6. 中华人民共和国卫生部. 中药新药临床研究指导原则. 1997-06-36.
7. 李博, 李峰, 吴泰相. 参附脱毒胶囊治疗阿片类急性戒断综合征的系统评价. 中国循证医学杂志, 2005, 10(9): 684-691.
8. 钟文昭, 吴一龙, 谷力加. Review Manager (RevMan)----临床医师通向Meta 分析的桥梁. 循证医学, 2013, 3(4): 234-246.
9. 秦献魁, 李萍, 刘建平. 小柴胡汤治疗慢性乙型肝炎随机对照试验的系统评价. 中西医结合学报, 2010, 8(4): 312-320.
10. 黄智芬, 黎汉中, 陈蔚, 等. 健脾消积口服液改善晚期肝癌患者生存质量32例临床观察. 中医杂志, 2004, 45(10): 751-756.
11. 黄智芬, 黎汉忠, 陆永奎, 等. 健脾消积口服液结合西药治疗II、III期肝癌40例的临床观察. 中国中西医结合杂志, 2003, 10(3): 192-194.
12. 黄能, 刘俊波, 黄常江. 健脾消痞汤治疗中晚期原发性肝癌32例. 中华实用中西医杂志, 2006, 8(9): 1161-1162.
13. 陈强松, 裴润琼, 欧武, 等. 健脾养肝汤治疗中晚期肝癌临床研究.中医学报, 2010, 9(5): 830-831.
14. 陆群英, 李坚, 彭海燕. 柴芍六君子汤对晚期原发性肝癌患者生活质量的影响.中医学报, 2014, 8(5): 637-638.
15. 覃清清, 韦劲松, 许瑞琪. 健脾扶正汤对晚期原发性肝癌患者生活质量的影响.中医学报, 2013, 9(5): 632-634.
16. 陈敏, 沈健, 周徐涛. 中西医结合治疗中晚期乙肝病毒性肝癌疗效观察. 实用中医药杂志, 2014, 7(1): 29-30.
17. 黄智芬, 韦劲松, 黎汉忠, 等. 中医时间疗法与中西药联合治疗对晚期胃癌生存质量的影响. 中医学报, 2011, 26(8): 901-903.
18. 唐健元, 马莉, 张磊. 欧美肿瘤药物评价策略简介及思考. 中华肿瘤杂志, 2008, 30(10): 798-800.
19. 王科, 张颖. 肝癌疼痛的中医外治概况及思考. 中国医药导报, 2013, 10(15): 138-140.
20. 秦献魁, 李萍, 刘建平, 等. 小柴胡汤治疗慢性乙型肝炎随机对照试验的系统评价. 中西医结合学报, 2010, 8(4): 312-320.
21. 刘建平. 随机对照试验的报告. 中国中西医结合杂志, 2005, 25(4): 297-298.

Previous Article
Efficacy and Safety of Intravenous Immunoglobulin for Severe Hand, Foot and Mouth Disease in China: A Meta-analysis

Chinese Journal of Evidence-Based Medicine

Effects of Liujunzi Decoction on the Quality of Life of Patients with Advanced Primary Liver Cancer: A Meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content